SCHEMBL10094415

SCHEMBL10094415

CC(C)c1ccc(F)cc1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 1/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ AKR1C3 P42330 3/20 0.47
▸ AKR1C2 P52895 3/20 0.47
▸ PTPN5 P54829 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ HTR2A P28223 1/20 0.40
▸ HTR2C P28335 1/20 0.40
▸ HTR2B P41595 1/20 0.40
▸ PDE2A O00408 1/20 0.40
▸ KIT P10721 1/20 0.39
▸ DDR1 Q08345 1/20 0.39
▸ NPY5R Q15761 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24910318 0.89 AKR1C3 (0.47) AKR1C3AKR1C2PTPN5ALDH1A1GAA
SCHEMBL26383335 0.86 PDE2A (0.39) KCNA5KCNH2AKR1C3AKR1C2TDP1
SCHEMBL21508375 0.84 AKR1C3 (0.43) AKR1C3AKR1C2PTPN5ALDH1A1GAA
SCHEMBL23479730 0.83 PTPN5 (0.57) AKR1C3AKR1C2PTPN5ALDH1A1GAA
SCHEMBL10094438 0.83 AKR1C3 (0.43) KCNH2AKR1C3AKR1C2PDE2A
SCHEMBL26382500 0.81 NOTUM (0.36) KCNA5KCNH2AKR1C3AKR1C2PDE2A
SCHEMBL10094660 0.80 SLC1A3 (0.47) KCNA5KCNH2AKR1C3AKR1C2TDP1
SCHEMBL10094400 0.80 ACHE (0.47) AKR1C3AKR1C2HTR2BNPY5RCHRM3
SCHEMBL24910270 0.80 PDE2A (0.46) KCNH2AKR1C3AKR1C2PDE2A
SCHEMBL24910273 0.79 AKR1C3 (0.44) KCNA5KCNH2AKR1C3AKR1C2PTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 — — US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885AKR1C3 1765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback